Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunkyu Kim

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Nature Communications|June 4, 2021
Crowdsourced mapping of unexplored target space of kinase inhibitorsAnna Cichońska, Balaguru Ravikumar, Robert J Allaway, et al.
The Journal of Cell Biology|January 28, 2021
The deubiquitylase USP9X controls ribosomal stallingAnne Clancy, Claire Heride, Adán Pinto-Fernández, et al.
The Journal of Cell Biology|February 18, 2021
Correction: The deubiquitylase USP9X controls ribosomal stallingAnne Clancy, Claire Heride, Adán Pinto-Fernández, et al.
Journal of Medicinal Chemistry|March 23, 2018
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast CancerGeorge S Tria, Tinya Abrams, Jason Baird, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of INCB126503 as a Potent and Selective FGFR2/3 InhibitorMinh H Nguyen, Anlai Wang, Lisa Truong, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Cell Systems|July 26, 2020
Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and TranscriptomicsMi Yang, Francesca Petralia, Zhi Li, et al.
ACS Medicinal Chemistry Letters|March 18, 2026
Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent MechanismRobert A Swyka, Evan D Styduhar, Anlai Wang, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Elife|October 12, 2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Nature Communications|June 4, 2021
Crowdsourced mapping of unexplored target space of kinase inhibitorsAnna Cichońska, Balaguru Ravikumar, Robert J Allaway, et al.
The Journal of Cell Biology|January 28, 2021
The deubiquitylase USP9X controls ribosomal stallingAnne Clancy, Claire Heride, Adán Pinto-Fernández, et al.
The Journal of Cell Biology|February 18, 2021
Correction: The deubiquitylase USP9X controls ribosomal stallingAnne Clancy, Claire Heride, Adán Pinto-Fernández, et al.
Journal of Medicinal Chemistry|March 23, 2018
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast CancerGeorge S Tria, Tinya Abrams, Jason Baird, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of INCB126503 as a Potent and Selective FGFR2/3 InhibitorMinh H Nguyen, Anlai Wang, Lisa Truong, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Cell Systems|July 26, 2020
Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and TranscriptomicsMi Yang, Francesca Petralia, Zhi Li, et al.
ACS Medicinal Chemistry Letters|March 18, 2026
Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent MechanismRobert A Swyka, Evan D Styduhar, Anlai Wang, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Elife|October 12, 2021
USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinomaE Josue Ruiz, Adan Pinto-Fernandez, Andrew P Turnbull, et al.
Pageof 7